Skip to content
Every compound links to batch-tested stock at Nordapep, with a Certificate of Analysis per batch.
peptide.wiki
Nordapep

Metabolic & incretin research

GLP-1, GIP, glucagon and amylin receptor agonists, the most heavily studied peptide class of the decade.

MetabolicApproved prescription medicine

Semaglutide

Long-acting GLP-1 receptor agonist

Evidence
5/5
MetabolicApproved prescription medicine

Tirzepatide

Dual GIP and GLP-1 receptor agonist

Evidence
5/5
MetabolicInvestigational

Retatrutide

Investigational GIP, GLP-1 and glucagon triple agonist

Evidence
4/5
Nordapep from
£63.40
£5.09/mg
MetabolicApproved prescription medicine

Liraglutide

First-generation acylated GLP-1 receptor agonist

Evidence
5/5
MetabolicInvestigational

Cagrilintide

Long-acting amylin and calcitonin receptor agonist

Evidence
4/5
MetabolicApproved prescription medicine

Exenatide

Gila-monster-derived GLP-1 receptor agonist

Evidence
5/5
MetabolicApproved prescription medicine

Pramlintide

Soluble amylin analogue

Evidence
5/5
MetabolicNot approved

AOD-9604

Modified fragment of the growth hormone tail

Evidence
2/5
MetabolicInvestigational

Survodutide

Investigational GLP-1 and glucagon receptor dual agonist

Evidence
4/5
MetabolicApproved in China

Mazdutide

GLP-1 and glucagon receptor dual agonist, approved in China

Evidence
4/5
Compare 3 side by side →

Comparisons in this area

Semaglutide vs Tirzepatide →Tirzepatide vs Retatrutide →Semaglutide vs Retatrutide →Liraglutide vs Semaglutide →Semaglutide vs Cagrilintide →Exenatide vs Liraglutide →Pramlintide vs Cagrilintide →Survodutide vs Retatrutide →Mazdutide vs Survodutide →
For laboratory research only. Nothing on peptide.wiki is medical advice. The compounds described are not for human or veterinary use, and research-grade material is not a medicine.